561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours

P LoRusso; M Fakih; F.Y.F.L De Vos; J.T Beck; J Merchan; G Shapiro; C-C Lin; J Desai; J Spratlin; T Cascella; L Sandalic; A.M Abdelhady; A Boran; E Gasal; F Janku; E Van Cutsem

doi:10.1016/j.annonc.2020.08.675

Back

561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours

Journal article

Peer reviewed

561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours

P LoRusso, M Fakih, F.Y.F.L De Vos, J.T Beck, J Merchan, G Shapiro, C-C Lin, J Desai, J Spratlin, T Cascella, …

Annals of oncology, Vol.31, pp.S484-S484

2020-09

DOI: https://doi.org/10.1016/j.annonc.2020.08.675

Metrics

10 Record Views

3 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.151 Pancreas & Gall Bladder Disorders; 1.151.395 Pancreatic Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: 561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours
Creators: P LoRusso - Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA
M Fakih - Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA
F.Y.F.L De Vos - Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands
J.T Beck - Medical Oncology, Highlands Oncology Group, Fayetteville, AR, USA
J Merchan - Medicine, University of Miami, Miami, FL, USA
G Shapiro - Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
C-C Lin - Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
J Desai - Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
J Spratlin - Gastrointestinal Oncology and Phase I Clinical Trials, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
T Cascella - Oncology, Novartis Pharma AG, Basel, Switzerland
L Sandalic - Oncology, Novartis Pharma AG, Basel, Switzerland
A.M Abdelhady - Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
A Boran - Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
E Gasal - Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
F Janku - Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
E Van Cutsem - Digestive Oncology, University Hospitals and KU Leuven, Leuven, Belgium
Publication Details: Annals of oncology, Vol.31, pp.S484-S484
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031598633202976